lynn slifer and regeneron, trading around $5 a share.e time it was a biotech that had been kick around for 17 years. 17 years without ever really developing anything note worthy that could move the needle since then, this company has become a powerhouse with the stock taking off into the stratosphere based on the surprising strength of a drug called ilea, its blockbuster macular degeneration formula, and a number of other therapies. fast forward ten years to this summer, 2015, and regeneron stock had traded all the way up to $592 before getting slammed by a sell-off. but forsake of using round numbers in this example, let's just call it 500 ten years ago what would happen with that $500 for buy in at 5? how about this a gain of roughly 9,900% no, regeneron is a ten-bagger. but you never could have gotten in on that gigantic gain if you hadn't taken a little risk in 2005 and bought a company with no profit, no products on the market, and only the promises of the ceo that things would work out. of course, regeneron worked out in a major wa

while pharma is lagging pricing issues r weighed on regeneron.by medicare advancement rules by precision-infuszed drugs and insight h faced lower prices on a key drug. the shadministration's ck on high prices is an increasing headwind for theharma ndustry, but analyst michael yee expects the specialty drugmakers will continue to tperform. >> you have some challenges as some of the large bioteches and large pharmaceutical companies and those challenges over the last few years have driven a likely move towards acquiring many of the small and mid-cap bioteches and we believe many of the other biotechs could be acquired and there's for the speed with which the companies are prodeveloping drugs and the potential of them being taken out. >> still, the price tag of some of the new drugs in the pipeline that offer cures will be in the million dollarange which wil pose a real challenge for the nation's health system. lyfor the nig business report, i'm bertha coombs. >> that is nightpo business for tonight. i'm tyler matheson. this is t te of year your pub

sizzle >> done, regeneron, sizzle or fizzle what do you say? to say fundamentally about this story, but just look at this chart here at carter braxton. this is a bearish to bullish reversal here above 400 now and it looks like a good bottoming formation to relatively cheap stock, great balance sheet and it seems like we ever got back in biotech m & a and it's going up >> time for the final trade around the horn. >> square, it's been on my ideal list at under $13. still long it's square. >> mike ko i would buy halliburton. >> stick around, we have a special guest and i'm going to detail a trade on how to get long ea. >> special, really >> yeah. very special. >> oh. >> guy >> nothing special about that guest coming on, but that guest will have a chat and i will have my oa jacket on because that's what i do. they told me last night, you better bring a jacket swiss. >> a wardrobe change coming up >> i call him discovery. >> "options action" right up after this $4.95 online equity trades? great question. see, for a full service brokerage like ours,

healthcare stocks with names like alumina, cerner, regeneron and that the pharmaceutical and that was where we had karl taking a massive stake in that and they're out with strong earnings with more than 80% of stocks in the s&p. a major 94% of them have been on earnings share. the healthcare sector has been very much the main driver by ministries rally this week. everybody moving higher except perkinelmer which is basically flat and regeneron which is half down a percent. this is our lead story. something just happened that looks like a scene out of the right stuff. to the heart of human spaceflight at johnson space center in houston, texas where hours ago this on your screen happen. nasa introduced the next generation of american astronauts. the men and women on your screen are going to be the first apply to the international space station aboard private rockets. who gets the nod to get the astronaut they are? turns out it's space x run by elon musk of tesla and aerospace giant, boeing. it's been more than seven years since the last space shuttle, the atlantis, launched from kennedy

i'm sure you set the trend for those guys also look at celegene, and bertha mentioned regeneron it'ser time period, but over the last six months or so, it's really rallied quite nicely the whole selktor is taking off here >> there are clear stakes between the two. the one is being biotech could be a one product company, and that makes it look easy. in fact, some of them can really blow up and i bought china biologics today. it's been a great stock off and on one at 1 10 per share. straightened below that, and one 18 per share >> china biologics >> they make blood operate in china >> gillead gild, stock is in the 70s. they're big big upside calls for the last several weeks watch that one, brian. >> upside calls, gillead, china logics thank you very much. the traders are taking your questions. all right. ready to go here all right. first up, a question from a veteran in chadsford, pennsylvania al asks, "what is -- -- why have they not had any of the stock moves following its earnings report >> it was most likely priced into the stock the stock is very expensive, and if you look at a lo

regeneron's approval of its eye drug was delayed by the fda. they will continue discussions with the regulator and will wait two months for a final decision. that delay could put them at a disadvantage versus its competitors, the stock fell a fraction to 366.45. >>> tesla's ceo says his claim last week was based on repeated conversations wit the saudis. in a blog post today elon musk said the saudi arabian sovereign wealth fund approached him many times. musk said he thought a deal could b closed. in a volatile session, the stock closed higher. >> from electric cars to an iconic motorcycle company. harley-davidsons being targeted by president trump again. he said over the weekend in a tweet that he supported a boycott of the bike maker. that sent shares ofow harley today, extending its recent slide. morgan brennen has more on this escalating feud. >> reporter: what happens when the president of the united statess support the boycott of an american brand? hainey-davidson may soon f out. after hosting a bikers for trump event over the weekend, pr

the company is weighing their options pre-while regeneron and amgen is down slightly.o some real weakness. have some interesting action around some of the canadian related assets. oil down 2.8%. , we had the canadian dollar down sharply against the u.s. dollar, not so much now. toronto stock exchange also lower this after headlines that the saudi's are considering selling their canadian assets and bonds. where we are seeing to a big decline, bitcoin is down 5.8%, well below the $7,000 per bitcoin mark. this good have something to do with the fact that sec is delaying a bitcoin back etf. mark: thanks, abigail. trade tensions keeping investors on edge, joining us now, john stoppard, -- john stopford. so many things to the shout -- john 3 -- to chat about. is attempting enough or not? john not yet, and possibly not ever. a situation which seems to be difficultng, so a planning environment for weaker borrowers. one beingiption from anti-orthodox and that is too early to anticipate. there are lots of scenarios. package, they need to adopt an orthodoxy. to repatriatecals sho

regeneron -- at 5.4% as cigna says the deal is on. and t-mobile at 3.6%.hey say the sprint deal is on track. lots of bullish activity. dave: we returned from apple to facebook. we were warned that russia would try to -- this week, we may have gotten the first confirmation. facebook is already detected several accounts that it said were engaged in "coordinated, inauthentic behavior," a euphemism for -- actively pursuing the question of tampering with the election. we welcome a member of the house intelligence committee, representative joaquin castro. knowus what we should about these latest reported attempts to use facebook to alter the elections. clear from: it is what facebook and twitter have threat from the russia and russian operatives trying to influence the election continues to be a huge threat for the united states and our election security. there is still an active russians to influence the american elections. as you know, we are only a few months from the midterm elections. i'm glad facebook is come forward. of the sociall media companies will co

other stocks that come to mind, regeneron in the health care space and cbs. we know the drama that's going on there if you do your homework and i'm not ready to make this call yet. i think there's a pony in there that i think you're supposed to buy but i'm not ready to make that call. >> good stuff. >>> unusual activity is next one stock to track that's up 15% in a week. stay tuned for what the options market are saying about it we're back in two minutes on halftime the digital divide is splitting this country. we have parents who are trying to get their kids off of too much social media and computers, and then we have parents who would only hope their children have access. middle school is a really key transition point, right. the stakes start changing. students begin to really start thinking about their futures. what i like about verizon's approach is that it's not limited to just giving kids new tools, it's really about empowering educators to teach in different ways, and exposing kids to more active forms of learning. giving technology is not a total solu

if you check on regeneron and celgene, up between 4 and 11%. however, not all big companies are participating. gilead is up about 3% this week, it has given back almost that much for this month, guys, so not everybody participating. it>> it's a good set up. celgene up 5%. >> i own it. >> that's 5% a month >>all athey were so oversold. these stocks cratered over the last look at allergan, most over the last year, that they were ripe to start to go upward once the bad news was priced in the other thing and meg, you talked about this, is that the political rhetoric, for whatever reason, these stocks react the worse in the summer before an election i don't know why that is you'd think the rhetoric would crescendo in september and october, but i found over these two-year psych ms, the stock prices do the worst in the summer that's time to buy them then they rally into the election so again here. >> lilly up 6%, merck up 5%, pfizer up 4% the space has been a great trade. >> yeah, and this is a -- >> mylan is 5%. >> pete is is the pharmas and biotechs